Home » GSK » Page 4

Tag Archives: GSK

AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug

Posted on by — No Comments ↓

At first glance, the list of features that distinguish AZD-0914 from other FQ seems impressive: broad Gram-positive and Gram-negative activity, MRSA and MSSA activity, potency against fluoroquinolone (FQ)-resistant isolates, low frequency for S. aureus resistance, and impressive activity against C. difficile. In addition, researchers mention a peculiar MoA for this gyrase/topoisomerase Continue reading AZD-0914: A New Broad-Spectrum Narrow-Development Path Drug→

Moving Towards Greater Transparency – One Step At A Time, Inexorably

Posted on by — No Comments ↓

Sharing trial data has been a controversial topic for quite a while. Recently the editors of major medical journals decided to take a stand. They will make access to trial source data a requirement, as a condition of publication, arguing that patients and the scientific community have a right to this Continue reading Moving Towards Greater Transparency – One Step At A Time, Inexorably→

Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)

Posted on by — No Comments ↓

When Roche inlicensed Polyphor’s anti-pseudomonas drug POL7080 in November 2013, it marked a turning point. It seemed that Big Pharma that had all but abandoned the field in the last decade and was getting engaged in anti-infectives again. When a company with as much experience in antibiotic drug development as Roche Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea  (Part 1)→